Medical Xpress quoted Jonathan Lovell  in an article about developing a novel immunotherapy approach to Alzheimer’s disease treatment that targets multiple epitopes.  

EIN Newswire reported that Pop Biotech, a biotechnology company developed by Jonathan Lovell, has developed an antibody-inducing peptide therapy. 

EIN Presswire reported that a biotech company founded by Johnathan Lovel, POP Biotechnologies, has moved into phase one of clinical trials for their new shingles vaccine. 

The Good Men Project reposted an article from Futurity that reported on a study, co-authored by Jonathan Lovell, in which UB researchers are developing a recombinant flu vaccine that would offer several advantages over conventional vaccines. 

UB researchers are developing a recombinant flu vaccine that would offer several advantages over conventional vaccines.